Operative and Nonoperative Treatment of Periprosthetic Humerus Fractures After Shoulder Arthroplasty: A Systematic Review and Meta-Analysis.

BACKGROUND: Periprosthetic humerus fracture is a relatively rare complication following shoulder arthroplasty. As shoulder arthroplasty volume increases, more periprosthetic fractures are anticipated. Some surgeons routinely operate on humerus shaft fractures adjacent to a humeral stem, while others recommend first-line nonoperative treatment. The purpose of this study was to identify and describe the prevalence of operative and nonoperative treatment options for periprosthetic humerus fractures, their associated outcomes, and complications. Our goal was to provide clinical insights for surgeons on the outcomes and complications associated with various treatment options. METHODS: We performed a systematic review of studies reporting clinical or radiographic outcomes and complications after operative or nonoperative treatment of postoperative periprosthetic humerus fractures following shoulder arthroplasty. Subgroup analysis was conducted for differences in surgical outcomes between open reduction internal fixation (ORIF) and revision arthroplasty. RESULTS: Twenty studies met the inclusion criteria (196 humeri). The mean clinical follow-up period was 2.6 years. Most fractures were Cofield B (42%), followed by C (27%), and A (12%); 19% were not classified. Forty-two percent of index implants were reverse total shoulders, 27% anatomic total shoulders, 16% hemiarthroplasties, and 1% resurfacing; implant design was not reported for 14%. The average time from index procedure to fracture was 2.9 years. One hundred sixty-seven (85%) fractures were treated operatively, 26 (13%) were treated nonoperatively, and 3 (2%) were missing information. Overall complication rate was 46%. Nonoperatively treated fractures had a higher complication rate (69% vs 43%, P = 0.04) and increased risk of malunion (19% vs 1%, P = < 0.001). Nonoperative management failed in 57% of Cofield B fractures. Time to union was shorter in the ORIF group than the revision arthroplasty group (24 weeks vs 30 weeks, P < 0.001). Among operatively treated fractures, revision arthroplasty was associated with more complications (61% vs 25%, P = 0.04) and higher nonunion rates (22% vs 0%, P = 0.008) than ORIF. CONCLUSIONS: Complications may be more frequent than previously understood. With a 70% healing rate, nonoperative management is a viable treatment option, but should be weighed against high risk of complications and need for future procedures, especially in Cofield B fractures. Treatment with ORIF is associated with a higher union rate and fewer complications than revision arthroplasty.

Cervical Disc Displacement in Military Pilots.

INTRODUCTION: Cervical disc displacement (CDD) may disqualify pilots from flying and have a profound impact on military unit capability. The objective of this retrospective database review is to characterize the incidence and demographic predictors of symptomatic cervical spine disc displacement in pilots of fixed- and rotary-wing aircraft and ground-based controls. MATERIALS AND METHODS: The Defense Military Epidemiology Database was queried for first-occurrence ICD-9 code 722.0: CDD cases from 2007 to 2015. Injury count rates among aircraft groups and overall incidence per 1,000 person-years were calculated and standardized for age, gender, and military rank, and 95% confidence intervals (CIs) were compared to determine significance. RESULTS: There were 934 new cases of CDD among active duty U.S. Military pilots during the study period. The overall incidence of CDD in all pilots during this time frame was 2.715 per 1,000 person-years (95% CI, 2.603-2.830). Helicopter pilots had a significantly higher incidence compared to all other aircraft pilots and crew at 3.79 per 1,000 person-years (95% CI, 3.48-4.13). This finding remained statistically significant after standardizing for age, gender, and rank. Among all military officers, increasing age was a risk factor for CDD. CONCLUSIONS: The U.S. Military helicopter pilots have an increased risk compared to fixed-wing pilots and non-pilot controls. CDD remains a rare, though career-threatening, condition. Increased education and awareness training are warranted for both helicopter pilots and flight physicians to recognize signs and symptoms of cervical pathology. Continued investigations into preventive measures to minimize injury and time unfit for flight are warranted.

Current concepts in ankle fractures.

Ankle fractures are among the most common orthopaedic injuries. Operative management is performed in unstable ankle fracture patterns to restore the stability and native kinematics of the ankle mortise and minimize the risk of post-traumatic degenerative changes. In this study, we review current concepts in ankle fracture management, including posterior malleolus fixation, syndesmosis fixation, deltoid ligament repair, fibular nailing, and early weightbearing, from both a biomechanical and clinical perspective.

Dose escalation therapy in previously untreated patients with multiple myeloma following Z-Dex induction treatment.

A phase I-II study of high-dose (HD) alkylating agents in newly diagnosed patients with multiple myeloma after maximum response to Z-Dex (idarubicin, dexamethasone) therapy and DHAP (cisplatin, HD cytosine arabinoside, dexamethasone), stem cell mobilization is reported. Twenty-six patients, median age 56 years (range 42-66), completed Z-Dex chemotherapy and peripheral blood stem cells (PBSC) were mobilized with DHAP. Patients then preceded to cyclophosphamide (HD Cy: 6 g/m(2)) with granulocyte colony-stimulating factor followed by busulphan-melphalan-conditioned PBSC autograft. Interferon alpha was introduced at 3 months post transplant as maintenance therapy. Six patients failed to complete the full protocol. Median time from diagnosis to transplantation was 8 months (range 6-12). Mean CD34+ cell dose collected was 15.8 x 10(6)/kg (CI 11.8, 19.8). Median time from DHAP to HD-Cy was 6 weeks (range 4-12) and from HD-Cy to transplant was 8 weeks (range 6-12). The median follow-up was 36 months (range 6-63). On an intent-to-treat basis, the response rates were three complete response (CR, 12%), 21 partial response (PR, 80%) and two stable disease (SD, 8%) post Z-Dex, five CR (19%) and 21 PR (81%) post HD-Cy, and 14 CR (54%) and 12 PR (46%) post transplant. The treatment-related mortality (TRM) was 4% (1 patient). Median overall survival (OS) and progression-free survival (PFS) have not been reached; estimated values were 60 and 48 months respectively. The 3-year OS and PFS were 72% and 62%. Actuarial 5-year OS and event-free survival were 49% and 32%. DHAP produces effective PBSC mobilization and sequential HD therapy, including autologous PBSCT, in patients who received Z-Dex; this offers significant durable disease response rates with acceptable TRM.